<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65917">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247739</url>
  </required_header>
  <id_info>
    <org_study_id>C1 3201</org_study_id>
    <nct_id>NCT02247739</nct_id>
  </id_info>
  <brief_title>A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor</brief_title>
  <official_title>A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Attacks in Patients With Hereditary Angioedema (HAE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharming Technologies B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharming Technologies B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the efficacy of recombinant human C1 inhibitor (rhC1INH) in the prophylaxis of
      angioedema attacks in patients with HAE

      Secondary Objective:

      To evaluate the safety and immunogenicity of recombinant human C1 inhibitor (rhC1INH) in the
      prophylaxis of angioedema attacks in patients with HAE
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design:

      This is a multi-center, randomized, double-blind, placebo-controlled, 3-period crossover
      study of rhC1INH in prophylaxis of angioedema attacks in patients with HAE.

      Medical screening (clinical and laboratory parameters) will be performed and patient medical
      history specific to HAE attacks will be collected to assess eligibility. Each patient will
      receive three 4 week periods of treatment twice weekly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of HAE attacks</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>20 weeks</time_frame>
    <description>anti-C1INH and anti-host related impurities (HRI) antibodies</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>rhC1INH twice weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhC1INH administered twice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhC1INH once weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rhC1INH administered once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Saline) twice weekly</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Saline) administered twice weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant human C1 inhibitor</intervention_name>
    <arm_group_label>rhC1INH twice weekly</arm_group_label>
    <arm_group_label>rhC1INH once weekly</arm_group_label>
    <other_name>rhC1INH</other_name>
    <other_name>Ruconest</other_name>
    <other_name>Conestat alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (Saline) twice weekly</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients fulfilling the following criteria at Screening are eligible for participation in
        the study:

          1. Age 13 years or older

          2. Laboratory confirmed diagnosis of HAE

          3. A history of frequent HAE attacks (at least 4 attacks per month across a minimum of 3
             consecutive months).

          4. Female patients of childbearing potential who are sexually active must be willing to
             use an acceptable form of contraception.

          5. Provided written informed consent (and written assent for minors)

          6. Willingness and ability to comply with all protocol procedures

        Exclusion Criteria:

        Patients who meet any of the following criteria at Screening are to be excluded from study
        participation:

          1. Patients with medical history of allergy to rabbits or rabbit-derived products
             (including rhC1INH)

          2. Diagnosis of acquired angioedema (AAE)

          3. Patients who are pregnant, or breastfeeding, or are currently intending to become
             pregnant

          4. Treatment with any investigational drug in the past 30 days

          5. Patients with any condition or treatment that, in the opinion of the Investigator,
             might interfere with the evaluation of study objectives

          6. Patients currently treated with angiotensin-converting enzyme (ACE) inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of South Florida Asthma, Allergy and Immunology Clinical Research Unit</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida, Asthma, Allergy &amp; Immunology Clinical Research Unit</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Division of Allergy and Immunology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baker Allergy, Asthma and Dermatology Research Center</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Allergy Research Corp</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G6C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital by St. Anna Brno, Department of clinical Immunology and Allergology</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Luigi Sacco Di Milano</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHI University Clinic of Dermatology</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Centrul Clinic Mediquest SRL</name>
      <address>
        <city>Singeorgiu de Mures</city>
        <state>Mures</state>
        <zip>547530</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Serbia</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 14, 2016</lastchanged_date>
  <firstreceived_date>September 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAE</keyword>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
